title: Antithrombin III Utilization in a Large Teaching Hospital.
abstract: In a retrospective study to assess the use of antithrombin concentrates, the authors judged the plasma-derived product (Thrombate III) to be more cost-effective than the recombinant human form (ATryn) for patients with hereditary antithrombin deficiency.
authors.forename: Cristina M
authors.initials: CM
authors.lastname: Salas
authors.forename: Marta A
authors.initials: MA
authors.lastname: Miyares
keywords: ATryn; Thrombate III; antithrombin; venoocclusive disease